Inclusion Criteria:

          -  Dose Escalation: have evidence of a solid tumor that is locally advanced and/or
             metastatic (excluding primary brain tumor)

          -  Dose Expansion: have evidence of a solid tumor as outlined below that is locally
             advanced and/or metastatic (excluding primary brain tumor)

               -  Cohort A: Human epidermal growth factor negative (HER2 negative) Breast Cancer
                  with an NF1 mutation

               -  Cohort B: Hormone receptor positive (HR+)/HER2 negative breast cancer after
                  progression on endocrine therapy and a CDK4/6 inhibitor

               -  Cohort C: PTEN loss or mutations

               -  Cohort D: KRAS G12C mutation

               -  Cohort E: KRAS G12D mutation

          -  Have adequate organ function

          -  Amenable to biopsy

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             scale

        Exclusion Criteria:

          -  Participating in medical research not compatible with this study

          -  Have not discontinued or recovered from previous treatments for cancer

          -  Have a significant cardiac condition

          -  Have untreated brain metastases

          -  Have a primary brain tumor

          -  Have a serious concomitant disorder

          -  Unable to swallow or digest pills

          -  Poorly controlled diabetes

          -  Concomitant medications or substances that are strong inhibitors/inducers of
             CYP3A.Study